We are live on ! Find out more
GILD icon

Gilead Sciences

1,888 hedge funds and large institutions have $98.5B invested in Gilead Sciences in 2024 Q4 according to their latest regulatory filings, with 291 funds opening new positions, 652 increasing their positions, 721 reducing their positions, and 93 closing their positions.

New
Increased
Maintained
Reduced
Closed

213% more first-time investments, than exits

New positions opened: 291 | Existing positions closed: 93

47% more funds holding in top 10

Funds holding in top 10: 1928 (+9)

13% more capital invested

Capital invested by funds: $87.4B → $98.5B (+$11.1B)

10% more funds holding

Funds holding: 1,7191,888 (+169)

1.53% more ownership

Funds ownership: 83.86%85.38% (+1.5%)

10% less repeat investments, than reductions

Existing positions increased: 652 | Existing positions reduced: 721

10% less call options, than puts

Call options by funds: $865M | Put options by funds: $959M

Holders
1,888
Holders Change
+169
Holders Change %
+9.83%
% of All Funds
24.87%
Holding in Top 10
28
Holding in Top 10 Change
+9
Holding in Top 10 Change %
+47.37%
% of All Funds
0.37%
New
291
Increased
652
Reduced
721
Closed
93
Calls
$865M
Puts
$959M
Net Calls
-$94.5M
Net Calls Change
-$124M
Name Holding Trade Value Shares
Change
Change in
Stake
EWM
326
Empirical Wealth Management
Washington
$13.1M +$485K +5,382 +4%
BS
327
Banco Santander
Spain
$13.1M -$11.9M -131,985 -48%
QCM
328
Quantinno Capital Management
New York
$12.9M +$5.25M +58,305 +71%
MSE
329
MUFG Securities EMEA
United Kingdom
$12.9M +$319K +3,542 +3%
Arrowstreet Capital
330
Arrowstreet Capital
Massachusetts
$12.9M -$257M -2,857,063 -95%
WCM
331
Westend Capital Management
California
$12.8M +$5.19M +57,632 +71%
PA
332
Profund Advisors
Maryland
$12.7M -$441K -4,902 -3%
Focus Partners Wealth
333
Focus Partners Wealth
Massachusetts
$12.6M +$3.01M +33,456 +33%
FMLI
334
Fukoku Mutual Life Insurance
Japan
$12.5M
Verition Fund Management
335
Verition Fund Management
Connecticut
$12.5M +$8.43M +93,663 +228%
TC
336
TownSquare Capital
Utah
$12.3M -$118K -1,311 -1%
IPAM
337
ICICI Prudential Asset Management
India
$12M -$2.07K -23 -0%
OAM
338
Oppenheimer Asset Management
New York
$11.9M -$4.94M -54,832 -30%
AF
339
Avanza Fonder
Sweden
$11.7M +$11.4M +127,115 New
AFA
340
Abacus FCF Advisors
Florida
$11.6M +$4.54M +50,408 +67%
ELC
341
Edgar Lomax Company
Virginia
$11.6M -$216K -2,400 -2%
KA
342
Kintegral Advisory
New York
$11.5M -$523K -5,807 -4%
CI Investments Inc
343
CI Investments Inc
Ontario, Canada
$11.4M +$435K +4,834 +4%
BPWM
344
Badgley Phelps Wealth Managers
Washington
$11.3M -$117K -1,300 -1%
PHK
345
Point72 Hong Kong
Hong Kong
$11.2M +$10.9M +120,867 New
GAI
346
General American Investors
New York
$11.1M -$2.25M -25,000 -17%
BB
347
Bell Bank
North Dakota
$10.9M +$499K +5,546 +5%
MSU
348
Mizuho Securities USA
New York
$10.9M +$3.37M +37,387 +46%
NAAA
349
New Age Alpha Advisors
New York
$10.8M +$10.5M +116,686 New
BCAM
350
Boston Common Asset Management
Massachusetts
$10.7M -$4.8M -53,301 -31%

GILD Hedge Fund Activity: Q4 2024 in Review

1,888 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q4 2024, worth a combined $98.5B — up 13% from $87.4B a quarter earlier.

Buyers outnumbered sellers: 291 funds opened new GILD positions and 93 closed out — a net gain of 198 holders — while 652 added to existing stakes and 721 trimmed.

The largest buyer was Bank of America, adding an estimated $944M. The largest seller was Capital World Investors, cutting an estimated $436M.

  • 1,888 institutional investors held Gilead Sciences (GILD) as of Q4 2024, up from 1,719 in Q3 2024.
  • Funds reported $98.5B of Gilead Sciences stock for Q4 2024, up 13% quarter-over-quarter.
  • 291 funds opened new Gilead Sciences positions in Q4 2024 and 93 closed out, a net change of +198 holders.
  • The largest Gilead Sciences buyer in Q4 2024 was Bank of America, an estimated $944M added.
  • The largest Gilead Sciences seller in Q4 2024 was Capital World Investors, an estimated $436M sold.

Based on aggregated 13F filings for Q4 2024.